237 related articles for article (PubMed ID: 22294416)
21. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
22. SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.
Wang CJ; Zhang ZZ; Xu J; Wang M; Zhao WY; Tu L; Zhuang C; Liu Q; Shen YY; Cao H; Zhang ZG
World J Gastroenterol; 2015 Jul; 21(27):8398-407. PubMed ID: 26217092
[TBL] [Abstract][Full Text] [Related]
23. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Tumour Biol; 2011 Jun; 32(3):451-9. PubMed ID: 21161468
[TBL] [Abstract][Full Text] [Related]
25. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
27. High expression of ROR2 in cancer cell correlates with unfavorable prognosis in colorectal cancer.
Mei H; Lian S; Zhang S; Wang W; Mao Q; Wang H
Biochem Biophys Res Commun; 2014 Oct; 453(4):703-9. PubMed ID: 25301559
[TBL] [Abstract][Full Text] [Related]
28. Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.
Davidson B; Hellesylt E; Holth A; Danielsen HE; Skeie-Jensen T; Katz B
Virchows Arch; 2017 Sep; 471(3):355-362. PubMed ID: 28643014
[TBL] [Abstract][Full Text] [Related]
29. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
30. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
31. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Wien Klin Wochenschr; 2004 Feb; 116(4):135-9. PubMed ID: 15038405
[TBL] [Abstract][Full Text] [Related]
33. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition.
Fourneaux B; Bourdon A; Dadone B; Lucchesi C; Daigle SR; Richard E; Laroche-Clary A; Le Loarer F; Italiano A
J Hematol Oncol; 2019 Jan; 12(1):11. PubMed ID: 30683135
[TBL] [Abstract][Full Text] [Related]
34. A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma.
Azab B; Macedo FI; Cass SH; Ripat C; Razi SS; Picado O; Franceschi D; Livingstone AS; Yakoub D
Am J Surg; 2019 Aug; 218(2):323-328. PubMed ID: 30471808
[TBL] [Abstract][Full Text] [Related]
35. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
36. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
Wei ZW; Wu J; Huang WB; Li J; Lu XF; Yuan YJ; Xiong WJ; Zhang XH; Wang W; He YL; Zhang CH
EBioMedicine; 2020 Jul; 57():102850. PubMed ID: 32574962
[TBL] [Abstract][Full Text] [Related]
37. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.
Rasmussen NR; Debebe Z; Wright TM; Brooks SA; Sendor AB; Brannon AR; Hakimi AA; Hsieh JJ; Choueiri TK; Tamboli P; Maranchie JK; Hinds P; Wallen EM; Simpson C; Norris JL; Janzen WP; Rathmell WK
PLoS One; 2014; 9(12):e116101. PubMed ID: 25542006
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumors and leiomyosarcomas.
Katz SC; DeMatteo RP
J Surg Oncol; 2008 Mar; 97(4):350-9. PubMed ID: 18286477
[TBL] [Abstract][Full Text] [Related]
39. The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors.
He L; Yang Z; Zhou J; Wang W
Clin Transl Oncol; 2015 Jun; 17(6):438-45. PubMed ID: 25387569
[TBL] [Abstract][Full Text] [Related]
40. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
